KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 6037 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Heart Rate Variability Biofeedback for Substance Use Disorder: A Randomized Clinical Trial. PMID 41032322 · JAMA Psychiatry · 2025-Dec-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Landscape of Anesthesiology Perioperative Interventional Clinical Trials Registered in ClinicalTrials.gov. PMID 40938916 · Anesthesiology · 2025-Dec-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effects of Therapies on Proteinuria and eGFR in IgA Nephropathy: Meta-Analysis of Randomized Trials. PMID 40928891 · Clin J Am Soc Nephrol · 2025-Dec-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The application of avatrombopag in chronic liver disease patients with severe thrombocytopenia undergoing procedures in China: a prospective real-world cohort study. PMID 40638266 · Int J Surg · 2025-Dec-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Perioperative Systemic Therapy in Localized Renal Cell Carcinoma: Current Evidence and Future Directions. PMID 41536399 · Cureus · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY Trial. PMID 41426046 · Kidney Int Rep · 2025-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Glucagon-Like Peptide-2 (GLP-2) Analogues in Patients With Short Bowel Syndrome Dependent on Parenteral Support: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PMID 41424579 · JGH Open · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Impact of updated regulatory guidelines on study results in contemporary uncomplicated urinary tract infection clinical trials and implications for trial conduct and drug development: a comparative analysis with EAGLE-2 and EAGLE-3. PMID 41399629 · Contemp Clin Trials Commun · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Tertiary lymphoid structure-related RNA indicator as metastasis risk factor in nasopharyngeal carcinoma. PMID 41397929 · Clin Transl Med · 2025-Dec The record is eligible for oncology, human, randomized, Phase III, and time-to-event criteria. However, it is not eligible as a primary result report of a randomized drug trial. The study is a secondary/prognostic model analysis that uses a Phase III trial cohort for external validation. The abstract does not describe the drug intervention in the referenced trial or present its primary efficacy results. Therefore, it fails the 'drug_intervention' and 'original_result' (as a primary trial report) criteria for Kaplan-Meier digitization of a drug trial.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Development of an electrochemiluminescence assay to measure serum darbepoetin concentration in extremely preterm infants. PMID 41392547 · Bioanalysis · 2025-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design. PMID 41388832 · Future Oncol · 2025-Dec 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer. PMID 41383151 · Future Oncol · 2025-Dec 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Clinical trial landscape for stem cells in autoimmune and inflammatory diseases: a comprehensive analysis and path forward. PMID 41377249 · Ann Med Surg (Lond) · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the clarity AD open-label extension study. PMID 41355080 · Alzheimers Dement · 2025-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis. PMID 41344352 · Lancet Microbe · 2025-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study. PMID 41318310 · Dig Liver Dis · 2025-Dec 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis. PMID 41317156 · Eur J Heart Fail · 2025-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Bayesian Prediction of Event Times Using Mixture Model for Blinded Randomized Controlled Trials. PMID 41290204 · Stat Med · 2025-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
First-line treatment in EGFR-mutated non-small cell lung cancer: brief report of an individual patient data comparison of phase 3 clinical trials. PMID 41270639 · Lung Cancer · 2025-Dec 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H S B
严格 v3 独有 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Efficacy of lurasidone on anxiety symptoms in patients with schizophrenia: A pooled post hoc analysis of five randomized, placebo-controlled trials. PMID 41262722 · PCN Rep · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Immunogenicity and safety of Biological E's CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A prospective double-blind randomized phase III clinical study. PMID 41245642 · IJID Reg · 2025-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Early stoppage of empirical antibiotic therapy in paediatric acute leukaemia with high-risk febrile neutropenia: a randomized, open-label, phase 3, non-inferiority trial. PMID 41245542 · EClinicalMedicine · 2025-Dec The study is an eligible oncology RCT with drug intervention, but its primary efficacy endpoint is a binary proportion (fever recurrence), not a time-to-event endpoint. Therefore, it does not meet the specific requirement for Kaplan-Meier/HR-based efficacy analysis.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adaptive designs in randomized clinical trials: reanalysis of the HOVON87/NMSG18 multiple myeloma trial. PMID 41245539 · EClinicalMedicine · 2025-Dec This is a methodological reanalysis of an existing Phase III trial, not the original trial report. The abstract does not specify the drug intervention used in the HOVON87/NMSG18 trial, only referencing it as a 'novel drug' trial. The primary focus is on evaluating adaptive trial designs, not reporting the original efficacy results of a specific drug regimen.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Systematic review and network meta-analysis: evaluation of systemic therapies for platinum refractory or resistant small cell lung cancer. PMID 41197381 · Lung Cancer · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effectiveness of immune checkpoint inhibitor therapy in thyroid cancer: A systematic review. PMID 41192027 · Cancer Treat Rev · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
High Virologic Suppression and Favorable Profiles of Two-Drug Antiretroviral Regimens in Africa: A Systematic Review of Current Evidence. PMID 41146527 · Clin Pharmacol Ther · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Types and Rates of Major Adverse Cardiovascular Events in Antithrombotic Trials: A Systematic Review and Meta-Analysis. PMID 41137817 · Can J Cardiol · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Integrating a pilot study and large trial into one adaptive design. PMID 41135812 · Contemp Clin Trials · 2025-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III Trials. PMID 41134450 · Dermatol Ther (Heidelb) · 2025-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Overlooked and underreported: A systematic review of quality of life in recent Phase III metastatic breast cancer trials. PMID 41130338 · J Cancer Policy · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Viloxazine Extended-Release: A Review in Attention-Deficit/Hyperactivity Disorder in Adults. PMID 41123831 · CNS Drugs · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A Time and Motion Study Comparing Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab in Combination with Chemotherapy for the Treatment of Metastatic Non-small Cell Lung Cancer. PMID 41116141 · Adv Ther · 2025-Dec The record describes a secondary, operational efficiency analysis (time-and-motion study) conducted alongside a phase 3 trial. It does not report the trial's primary or key secondary time-to-event efficacy outcomes (e.g., OS, PFS) and is therefore ineligible for a Kaplan-Meier digitization cohort focused on efficacy endpoints.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial. PMID 41109921 · Nat Med · 2025-Dec 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 2 Figure · 6 Panel · risk visible
Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials. PMID 41107641 · Pain Ther · 2025-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata. PMID 41083802 · Dermatol Ther (Heidelb) · 2025-Dec The record describes a protocol for a Phase 3 trial in alopecia areata (a non-malignant condition). The primary endpoint is a categorical response (SALT score ≤20), not a time-to-event endpoint like OS, PFS, or TTP. It does not report results; it is a protocol/design paper.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Targeting IL-6 Receptor Signaling with Satralizumab in Thyroid Eye Disease: Design of the Phase 3 SatraGO-1 and SatraGO-2 Trials. PMID 41066062 · Ophthalmol Ther · 2025-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Improvement in Motor Consistency and Stability with Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: Post Hoc Analysis of Two Phase 3 Clinical Trials. PMID 41045349 · Neurol Ther · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Ifupinostat: First Approval. PMID 41028651 · Drugs · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
VER-01 Shows Enhanced Gastrointestinal Tolerability, Superior Pain Relief, and Improved Sleep Quality Compared to Opioids in Treating Chronic Low Back Pain: A Randomized Phase 3 Clinical Trial. PMID 41028525 · Pain Ther · 2025-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Evaluating clazosentan sodium for the treatment of aneurysmal subarachnoid hemorrhage. PMID 41024416 · Expert Rev Neurother · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Maintenance after first-line treatment for advanced soft tissue sarcoma. PMID 40975452 · Crit Rev Oncol Hematol · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Quality of life results and survival outcomes in trials of immunotherapy in advanced cancers: A systematic review and meta-research study. PMID 40975451 · Crit Rev Oncol Hematol · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Reply: A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The PRIME Study. PMID 40928028 · J Urol · 2025-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Re: Effect of NeuroSAFE-guided RARP Versus Standard RARP on Erectile Function and Urinary Continence in Patients with Localised Prostate Cancer (NeuroSAFE PROOF): A Multicentre, Patient-blinded, Randomised, Controlled Phase 3 Trial. PMID 40796479 · Eur Urol · 2025-Dec The study is a randomized Phase 3 trial in oncology, but it investigates a surgical intervention (non-drug) and reports functional outcomes, not the required time-to-event efficacy endpoints.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The evolution of treatment for pediatric advanced stage classic Hodgkin lymphoma - a narrative literature review. PMID 40776670 · Leuk Lymphoma · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics. PMID 40683616 · Am Heart J · 2025-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Design and rationale of the HARTc 2.0 trial: A multicenter randomized controlled study on the impact of point-of-care high-sensitivity cardiac troponin-I testing in prehospital acute coronary syndrome triage on diagnosis and cost-effectiveness. PMID 40675207 · Am Heart J · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
New targets in diabetic retinopathy: addressing limitations of current treatments through the Sema3A/Nrp1 pathway. PMID 40634736 · Eye (Lond) · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Tenecteplase in Central Retinal Artery Occlusion Study (TenCRAOS): Protocol for a randomized-controlled trial. PMID 40509553 · Eur Stroke J · 2025-Dec 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy of Cerebrolysin Treatment as an Add-On Therapy to Mechanical Thrombectomy in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion in Anterior Circulation: Results of a 3-Month Follow-up of a Prospective, Open Label, Single-Center Study. PMID 40325343 · Transl Stroke Res · 2025-Dec 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -